Marinomed’s first marketed product based on the MAVIREX platform is an anti-viral nasal spray for the prevention and treatment of common cold. The product is a sterile nasal spray that is currently marketed in Austria, Israel, Turkey, UK and was further out-licensed for 54 countries to Boehringer Ingelheim to all of Europe (except Austria, UK and Ireland), Russia & CIS, South America and Australia in 2010 as well as for 19 countries to local partners worldwide.
The product is registered as medical device class IIa in Europe since 2007 and is sold as an over-the-counter (OTC) product allowing direct to consumer marketing.
Two clinical studies were conducted with the anti-viral nasal spray against common cold, one in adults and another trial in small children. An anti-viral claim “Sterile solution for the wetting of the nasal mucosa with anti-viral effect in common cold.” was granted for the product based on the clinical results and appears on the product packaging.
Marinomed has received patents worldwide to protect the MAVIREX platform and its products. Patent protection lasts until end of 2027; the core patent was granted in 03/2010.